Drug intelligence / Profile preview

CJRB-101 + pembrolizumab

Development stage: Unknown
Lead developer: CJ Bioscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Intravenous

Overview

CJRB-101 + pembrolizumab is a combination therapy consisting of CJRB-101, a live biotherapeutic product, and pembrolizumab, an immune checkpoint inhibitor. This combination is being investigated for the treatment of advanced or metastatic cancers. CJRB-101 appears to work through TLR4-dependent stimulation of key immune cell populations (macrophages, CD8+ T cells, neutrophils), while pembrolizumab is a PD-1 inhibitor. The combination aims to address the unmet medical needs of low response rates and refractoriness to immune checkpoint inhibitors in certain cancer populations.

Targets

TLR4 (Toll-like receptor 4)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on CJRB-101 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJRB-101 + pembrolizumab.

Explore the full profile